$PMVP
PMV Pharmaceuticals, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024093343 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.941M $5.542M
YoY Change -18.2% -11.74%
% of Gross Profit
Research & Development $16.95M $14.63M
YoY Change 24.74% 5.67%
% of Gross Profit
Depreciation & Amortization $371.0K $372.0K
YoY Change 3.63% 0.81%
% of Gross Profit
Operating Expenses $21.89M $20.17M
YoY Change 11.51% 0.24%
Operating Profit -$21.89M -$20.17M
YoY Change 11.51% 0.24%
Interest Expense $2.615M $2.801M
YoY Change -12.25% 3.89%
% of Operating Profit
Other Income/Expense, Net $2.736M $2.784M
YoY Change -8.43% 3.49%
Pretax Income -$19.15M -$17.39M
YoY Change 15.1% -0.26%
Income Tax $74.00K -$16.17M
% Of Pretax Income
Net Earnings -$19.23M -$1.213M
YoY Change 15.54% -93.04%
Net Earnings / Revenue
Basic Earnings Per Share -$0.37 -$0.02
Diluted Earnings Per Share -$0.37 -$0.02
COMMON SHARES
Basic Shares Outstanding 51.52M 51.44M
Diluted Shares Outstanding 51.57M 51.48M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $197.9M $212.9M
YoY Change -16.87% -2.71%
Cash & Equivalents $48.81M $48.53M
Short-Term Investments $149.1M $164.4M
Other Short-Term Assets $6.779M $5.870M
YoY Change 99.38% 76.49%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $189.6M $218.8M
YoY Change -7.64% 14.9%
LONG-TERM ASSETS
Property, Plant & Equipment $10.13M $10.53M
YoY Change -6.39% -5.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $15.10M $0.00
YoY Change -58.3% -100.0%
Other Assets $242.0K $182.0K
YoY Change 34.44% 0.55%
Total Long-Term Assets $33.88M $18.75M
YoY Change -39.22% -63.81%
TOTAL ASSETS
Total Short-Term Assets $189.6M $218.8M
Total Long-Term Assets $33.88M $18.75M
Total Assets $223.5M $237.5M
YoY Change -14.38% -1.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.063M $4.533M
YoY Change 22.94% 29.92%
Accrued Expenses $10.26M $5.701M
YoY Change 13.49% -28.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.56M $11.39M
YoY Change 26.57% -0.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.02M $11.84M
YoY Change -5.32% -8.65%
Total Long-Term Liabilities $12.02M $11.84M
YoY Change -5.32% -8.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.56M $11.39M
Total Long-Term Liabilities $12.02M $11.84M
Total Liabilities $25.59M $23.22M
YoY Change 9.28% -4.85%
SHAREHOLDERS EQUITY
Retained Earnings -$345.7M -$326.5M
YoY Change 17.49% 17.61%
Common Stock $543.2M $541.0M
YoY Change 2.07% 9.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $197.9M $214.3M
YoY Change
Total Liabilities & Shareholders Equity $223.5M $237.5M
YoY Change -14.38% -1.93%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$19.23M -$1.213M
YoY Change 15.54% -93.04%
Depreciation, Depletion And Amortization $371.0K $372.0K
YoY Change 3.63% 0.81%
Cash From Operating Activities -$16.84M -$1.598M
YoY Change 7.53% -87.61%
INVESTING ACTIVITIES
Capital Expenditures $1.000K $4.000K
YoY Change -98.0% -99.29%
Acquisitions
YoY Change
Other Investing Activities $17.12M $2.327M
YoY Change -150.97% -103.67%
Cash From Investing Activities $17.12M $2.323M
YoY Change -150.89% -103.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 141.0K
YoY Change -100.0% -93.38%
NET CHANGE
Cash From Operating Activities -16.84M -1.598M
Cash From Investing Activities 17.12M 2.323M
Cash From Financing Activities 0.000 141.0K
Net Change In Cash 280.0K 866.0K
YoY Change -101.73% -101.16%
FREE CASH FLOW
Cash From Operating Activities -$16.84M -$1.598M
Capital Expenditures $1.000K $4.000K
Free Cash Flow -$16.84M -$1.602M
YoY Change 7.19% -88.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001699382
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39539
dei Entity Registrant Name
EntityRegistrantName
PMV PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3218129
dei Entity Address Address Line1
EntityAddressAddressLine1
One Research Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Princeton
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08540
dei City Area Code
CityAreaCode
609
dei Local Phone Number
LocalPhoneNumber
642-6670
dei Security12b Title
Security12bTitle
Common stock, par value $0.00001
dei Trading Symbol
TradingSymbol
PMVP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
51519751
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48526000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37706000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
822000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
822000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
164393000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
165351000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5048000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3530000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
218789000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
207409000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10530000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10666000
CY2024Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
25505000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8038000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8382000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
182000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
190000
CY2024Q2 us-gaap Assets
Assets
237539000
CY2023Q4 us-gaap Assets
Assets
252152000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4533000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3237000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5701000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9940000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1151000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
852000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11385000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14029000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11839000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12434000
CY2024Q2 us-gaap Liabilities
Liabilities
23224000
CY2023Q4 us-gaap Liabilities
Liabilities
26463000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51522125
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51522125
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51445862
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51445862
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
540986000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
535468000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-326486000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310003000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-185000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
224000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
214315000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
225689000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
237539000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
252152000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14628000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13843000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27813000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28916000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5542000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6279000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10578000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12686000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
20170000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
20122000
us-gaap Operating Expenses
OperatingExpenses
38391000
us-gaap Operating Expenses
OperatingExpenses
41602000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20170000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20122000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38391000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41602000
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2801000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2696000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5753000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5022000
CY2024Q2 pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-17000
CY2023Q2 pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-6000
pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-18000
pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
20000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2784000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2690000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5735000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5042000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17386000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17432000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32656000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36560000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-16173000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-16173000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1213000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17436000
us-gaap Net Income Loss
NetIncomeLoss
-16483000
us-gaap Net Income Loss
NetIncomeLoss
-36564000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-61000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-212000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-380000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
117000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-28000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-56000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-212000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-408000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
117000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1269000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17648000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16891000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36447000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.8
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.8
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51478751
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51478751
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45813132
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45813132
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51462307
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51462307
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45793355
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45793355
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
246028000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2932000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-19128000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
329000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
230173000
CY2023Q2 pmvp Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans
ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
105000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2026000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3153000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17436000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-212000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
217809000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
225689000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2610000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-15270000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-319000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-34000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
212676000
CY2024Q2 pmvp Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans
ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
141000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2767000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1213000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-61000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
214315000
us-gaap Profit Loss
ProfitLoss
-16483000
us-gaap Profit Loss
ProfitLoss
-36564000
us-gaap Share Based Compensation
ShareBasedCompensation
5377000
us-gaap Share Based Compensation
ShareBasedCompensation
6085000
us-gaap Depreciation
Depreciation
734000
us-gaap Depreciation
Depreciation
540000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3004000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1669000
pmvp Other Non Cash Lease Income Expense
OtherNonCashLeaseIncomeExpense
193000
pmvp Other Non Cash Lease Income Expense
OtherNonCashLeaseIncomeExpense
188000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-7000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1518000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2758000
pmvp Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-241000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses. Actual results could differ materially from those estimates.</span></p>
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
3004000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
1670000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
822000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
822000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1296000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
493000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4239000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
632000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17782000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27913000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
598000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
721000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
71374000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
129552000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
100461000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
115955000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28489000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14318000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2026000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
141000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
117000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
141000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2143000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-28000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10820000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-40088000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38528000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
109119000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49348000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
69031000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1213000
us-gaap Net Income Loss
NetIncomeLoss
-16483000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17782000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-326486000
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
212919000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
213022000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
193000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
212831000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
228359000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
191000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
228550000
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
48526000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
37706000
CY2024Q2 us-gaap Marketable Securities
MarketableSecurities
164393000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
164393000
CY2024Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
190856000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
165351000
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
25505000
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14535000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13936000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4005000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3270000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10530000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10666000
CY2024Q2 us-gaap Depreciation
Depreciation
372000
CY2023Q2 us-gaap Depreciation
Depreciation
369000
us-gaap Depreciation
Depreciation
734000
us-gaap Depreciation
Depreciation
540000
CY2024Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2998000
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
4498000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
280000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
172000
CY2024Q2 pmvp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
2423000
CY2023Q4 pmvp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5270000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5701000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9940000
CY2018Q3 pmvp Number Of Noncancelable Operating Leases
NumberOfNoncancelableOperatingLeases
2
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
355000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
596000
us-gaap Operating Lease Cost
OperatingLeaseCost
709000
us-gaap Operating Lease Cost
OperatingLeaseCost
1193000
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
228000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
311000
us-gaap Variable Lease Cost
VariableLeaseCost
361000
us-gaap Variable Lease Cost
VariableLeaseCost
630000
CY2024Q2 us-gaap Lease Cost
LeaseCost
583000
CY2023Q2 us-gaap Lease Cost
LeaseCost
907000
us-gaap Lease Cost
LeaseCost
1070000
us-gaap Lease Cost
LeaseCost
1823000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8038000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8382000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1151000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
852000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11839000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12434000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12990000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
13286000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y11M1D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y5M1D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
pmvp Net Cash Paid Received For Amounts Included In The Measurement Of Lease Liabilities
NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities
662000
pmvp Net Cash Paid Received For Amounts Included In The Measurement Of Lease Liabilities
NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities
1382000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10000
CY2024Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsRemainderOfFiscalYear
912000
CY2024Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths
1869000
CY2024Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Two
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo
1925000
CY2024Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Three
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree
1983000
CY2024Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Four
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour
2042000
CY2024Q2 pmvp Lessee Operating Lease Liability To Be Paid Net Of Repayments After Year Four
LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFour
7453000
CY2024Q2 pmvp Lessee Operating Lease Liability Payments Net Of Repayments Due
LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue
16184000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3194000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12990000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
355000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
596000
us-gaap Operating Lease Expense
OperatingLeaseExpense
709000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1193000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51522125
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51445862
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
514434
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4474411
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6973464
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.44
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
990000
pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Reserved For Issuance
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance
2572174
pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
3321070
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3321070
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.78
pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
1548555
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1548555
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.99
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3111
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.8
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5274070
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8742868
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.61
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M19D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
231000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8742868
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.61
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y5M19D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
231000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4207339
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M9D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
222000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
14576000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0382
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0469
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0345
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0395
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
236296
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
13.6
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
952665
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.8
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
52550
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
3.5
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1136411
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.18
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2767000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3153000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5377000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6085000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2767000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3153000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5377000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6085000
CY2024Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.926
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
pmvp Expected Cash Received From Sale Of Unsued Net Operating Loss Carryforwards And Rd Tax Credits
ExpectedCashReceivedFromSaleOfUnsuedNetOperatingLossCarryforwardsAndRDTaxCredits
16176000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9901023
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7563598

Files In Submission

Name View Source Status
0000950170-24-093343-index-headers.html Edgar Link pending
0000950170-24-093343-index.html Edgar Link pending
0000950170-24-093343.txt Edgar Link pending
0000950170-24-093343-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pmvp-20240630.htm Edgar Link pending
pmvp-20240630.xsd Edgar Link pending
pmvp-ex31_1.htm Edgar Link pending
pmvp-ex31_2.htm Edgar Link pending
pmvp-ex32_1.htm Edgar Link pending
pmvp-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
pmvp-20240630_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable